tradingkey.logo
tradingkey.logo
Search

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

ReutersApr 7, 2026 11:10 AM

- Ascletis Pharma Inc 1672.HK:

  • ASCLETIS ANNOUNCES FIXED-DOSE COMBINATION OF ASC30, ONCE-DAILY ORAL SMALL MOLECULE GLP-1R AGONIST, AND ASC39, ONCE-DAILY ORAL SMALL MOLECULE AMYLIN-SELECTIVE AMYLIN RECEPTOR AGONIST, FOR CLINICAL DEVELOPMENT

  • ASCLETIS PHARMA INC - EXPECTS IND SUBMISSION TO FDA FOR ASC30_39 FDC IN Q3 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI